PhaseBio Pharmaceuticals, Inc.
Other OTCTotal Valuation
PhaseBio Pharmaceuticals, Inc. carries a market capitalization of - -, placing it among publicly traded companies globally. Its enterprise value stands at 26.66M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | - - |
| Enterprise Value | 26.66M |
Share Statistics
PhaseBio Pharmaceuticals, Inc. currently has 49.86M shares outstanding.
| Shares Outstanding | 49.86M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 35.57, and the price-to-book ratio stands at -0.07.
| PE Ratio | N/A |
| PS Ratio | 35.57 |
| PB Ratio | -0.07 |
| P/TBV Ratio | -0.25 |
| P/FCF Ratio | -0.51 |
| P/OCF Ratio | -0.49 |
Enterprise Valuation
| EV / Sales | 32.59 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
PhaseBio Pharmaceuticals, Inc. maintains a current ratio of 0.47, meaning it holds 0.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -4.58, indicating conservative leverage, while an interest coverage ratio of -152.18 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.47 |
| Quick Ratio | 0.32 |
| Debt / Equity | -4.58 |
| Debt / EBITDA | -0.05 |
| Interest Coverage | -152.18 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -167.49 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
PhaseBio Pharmaceuticals, Inc.'s stock has declined approximately -99.99% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.
| Beta (5Y) | N/A |
| 52-Week Price Change | -99.99% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, PhaseBio Pharmaceuticals, Inc. generated 818,000.00 in revenue and converted that into -102.84M in net income, yielding earnings per share of -2.12. EBITDA reached -102.26M, while operating income came in at -104.20M.
| Revenue | 818,000.00 |
| Gross Profit | N/A |
| Operating Income | -104.20M |
| Pretax Income | -102.84M |
| Net Income | -102.84M |
| EBITDA | -102.26M |
| EBIT | -104.20M |
| Earnings Per Share (EPS) | -2.12 |
Balance Sheet
PhaseBio Pharmaceuticals, Inc. holds 7.80M in cash and equivalents against 5.37M in total debt, resulting in a net debt position of -3.73M. Total book value stands at -419.55M, with working capital of -13.11M providing operational flexibility.
| Cash & Cash Equivalents | 7.80M |
| Total Debt | 5.37M |
| Net Debt | -3.73M |
| Equity (Book Value) | -419.55M |
| Book Value Per Share | -8.65 |
| Working Capital | -13.11M |
Cash Flow
PhaseBio Pharmaceuticals, Inc. produced -59.42M in operating cash flow over the past twelve months. After subtracting -2.40M in capital expenditures, free cash flow totaled -61.82M - equivalent to -1.27 per share.
| Operating Cash Flow | -59.42M |
| Capital Expenditures | -2.40M |
| Free Cash Flow | -61.82M |
| FCF Per Share | -1.27 |
Margins
PhaseBio Pharmaceuticals, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -12,738.63 and net profit margin of -12,572.13 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -12,738.63 |
| Pretax Margin | -12,572.13 |
| Profit Margin | -12,572.13 |
| EBITDA Margin | -12,501.47 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -17.77 |
| FCF Yield | -195.98 |
Scores
PhaseBio Pharmaceuticals, Inc. posts an Altman Z-Score of -42.56, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -42.56 |